Novamab and GenOrigin Tech Forge Strategic Partnership to Accelerate Nanobody Drug Innovation
Novamab
Nanobody Innovative Drug Developer
Recently, Novamab and Yanin Tech announced a strategic partnership. Both parties will leverage their advanced technologies and expertise in the biopharmaceutical field to enhance acceleration.Nanobody Innovative DrugsThe R&D process.
Novamab is currently the only one in China withFull-process Development of Nanobody DrugsA company with capabilities has established an integrated, systematic, and comprehensive professional development platform.
Yan Yin Technology focuses on providing includingMolecular Biology Gene Editing Research Platform, Biomedical Large Model Library, Laboratory Process Automation SystemA comprehensive scientific research solution, including but not limited to.
Novamab COO Jing HuangSaid: "The professional capabilities and innovative technologies of Yan Yin Technology in the field of AI research services will provide strong support for our nanobody innovative drug development. We hope that through this cooperation, we can enhance the digital intelligence level of the company and preserve valuable data assets.”
Dr. Zeping Chen, Founder & CEO of Yan Yin TechnologySaid: "As a well-known enterprise in the respiratory and autoimmune fields focused on innovative nanobody drugs, Novamab is highly honored to collaborate. By utilizing YanYin ZhiYan Cloud, we will leverage...Integrated R&D Data Management and AI Large Model Technology", significantly enhancing the digital and intelligent capabilities of Novamab."
Novamab is an innovative biopharmaceutical company dedicated to the research, development, and industrialization of nanobody drugs. Established in October 2017, it is located in the Shanghai International Medical Park. Novamab has built a 500L Pichia pastoris nanobody GMP pilot production workshop, filling an industry gap in this field and demonstrating both scarcity and competitiveness.
As of September 2024, Novamab has applied for more than 80 domestic and international invention patents, with 31 authorized. Its R&D pipeline covers areas such as the respiratory system, autoimmune diseases, ophthalmology, and oncology, and it has currently obtained four clinical approvals.
Yan Yin TechnologyFocus on providing AI research collaboration platforms and solutions for the biopharmaceutical field, including molecular biology gene editing research platforms, biopharmaceutical large model libraries, laboratory process automation systems, data intelligent management, intelligent analysis prediction, and visualization software. Offer AI research services to major universities, research institutions, and pharmaceutical companies in China, helping researchers in the biopharmaceutical industry conduct scientific experiments and data analysis more efficiently, and improve the efficiency and quality of research.
Source of the article: Yan Yin Technology
